FDA approves new pancreatic cancer drug that could transform treatments

More from this show

The Food and Drug Administration (FDA) approved a pancreatic cancer drug experts predict could transform treatment for the deadly disease. Rasonque, or Daraxonrasib, was approved for patients with advanced pancreatic cancer who have already tried a prior treatment like chemotherapy. The drug is a daily pill that helps target a mutation in a gene called KRAS. This gene is found in almost all pancreatic cancers as well as other cancers, such as lung, colorectal and ovarian.

Rachna Shroff, MD, a Gastrointestinal Oncologist from Banner University Medicine, joined “Arizona Horizon” to discuss how this drug could change outcomes for this disease.

Shroff described Daraxonrasib as a game-changer for stage 4 pancreatic cancer patients. The drug targets a signaling pathway in pancreatic cancer, and has shown already unprecedented survival.

“It produces results that are better than chemotherapy and some of the data shows it improves quality of life for our patients,” she said.

The KRAS gene mutation is mutated in over 90% of pancreatic cancers, which drives uncontrolled cancer cell growth. Daraxonrasib cuts off the signaling pathway, preventing the cancer from spreading.

As for side effects, patients commonly experience rash and diarrhea. In response, Schroff said physicians are preemptively prescribing medications to prevent or reduce the severity of those issues.

Medical professionals are testing to see if Draxonrasib can treat other forms of cancer and what other drugs can come of KRAS inhibitors. This is only the tip of the iceberg, Shroff said.

“This is just the first of many drugs,” she said. “Hopefully, this is just the start of a sea change where we get a number of drug approvals coming through.”

Schroff said Draxonrasib is the start of a new era in cancer treatment.

“I’ve treated pancreas cancer for 16 years and the day that the press release came out, I started crying tears of joy. I’ve lost way too many patients to this disease and I knew the second I saw that data, and that press release, that this was going to be a turning tide,” she said.

Rachna Shroff, MD, Gastrointestinal Oncologist, Banner University Medicine

SPOTLIGHT

Arizona PBS wins 4 Emmy® awards in 2026

‘Crime and Punishment in America’ from Ken Burns

Donate your car or other vehicle to Arizona PBS

Join us for PBS Books Readers Club!

Subscribe to Arizona PBS Newsletters